Overview of Diuretic Strategies in Edematous States by Mahajan, MD, Kedar
The Medicine Forum
Volume 14 Article 7
2013
Overview of Diuretic Strategies in Edematous
States
Kedar Mahajan, MD
Thomas Jefferson University Hospitals, Kedar.Mahajan@jefferson.edu
Follow this and additional works at: http://jdc.jefferson.edu/tmf
Part of the Medicine and Health Sciences Commons
Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
The Medicine Forum by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Mahajan, MD, Kedar (2013) "Overview of Diuretic Strategies in Edematous States," The Medicine Forum: Vol. 14, Article 7.
Available at: http://jdc.jefferson.edu/tmf/vol14/iss1/7
12
Introduction
Considering potential physiologic causes of volume overload in 
clinical practice, such as heart failure, renal failure, nephrotic 
syndrome, or portal hypertension, may yield insight into 
directing therapy beyond switching from oral to intravenous 
diuretic therapy. Appropriate oral therapies that achieve effective 
diuresis may reduce costs, address shortages of intravenous loop 
diuretics, reduce the need for unnecessary inpatient admissions 
by facilitating outpatient management, allow earlier optimization 
of outpatient regimens, and decrease the length of hospital stay. 
Congestive Heart Failure
Decreased responsiveness to oral diuretics in either high or 
low output heart failure has been described. Goldman’s Cecil 
Medicine identifies factors such as gut edema, hypotension, 
reduced renal blood flow, and adaptive changes in the nephron.1 
Bowel wall edema from elevated systemic venous pressures in 
heart failure may decrease bioavailability of diuretics while 
increased renal afterload from venous congestion and intrinsic 
renal compromise from interstitial pressures impairs diuresis.2 
“Adaptive changes” are seen in long term loop diuretic use and 
include hypertrophy and hyperplasia of the distal convoluted 
tubule cells and increased Na+/Cl- - cotransporter activity 
which both contribute to increased sodium reabsorption.3 This 
adaption is partially addressed by blocking the reabsorption with 
thiazide/thiazide-like (e.g. hydrochlorothiazide or metolazone) 
diuretics and decreasing Na+/Cl- - cotransporter upregulation 
by inhibiting effects of aldosterone (e.g. spironolactone or 
eplerenone). 1, 3
Optimal outpatient management of diuresis in heart failure is 
often difficult. Doubling the oral dose of diuretics (furosemide, 
torsemide, and metolazone) does not affect left ventricular 
systolic or diastolic function, has been shown to improve 
symptoms and 6-minute walk distance after a 24 day endpoint.4 
Detrimental effects of high-dose diuretics in systolic dysfunction 
have be associated with increased mortality raising controversy, 
but confounding factors such as diuretic resistance or heart 
failure severity have made these links uncertain.5 The superior 
pharmacodynamic profile of toresemide (see Table 1) and its 
anti-aldosterone and vasorelaxation effect likely contributes to 
its better performance in improving left ventricular function, 
reduction of mortality, frequency/duration of heart-failure 
related hospitalization, quality of life, exercise tolerance and 
New York Heart Association functional class compared with 
furosemide.6, 7 Synergy of loop-diuretics with potassium sparing 
or thiazide diuretics is efficacious in persistent edematous states.8 
Additionally, inadequate tissue perfusion, signaled by increasing 
blood urea nitrogen or serum creatinine, can be addressed 
during diuresis in heart failure with inotropes or vasodilators.
Renal Disease
Patients with renal insufficiency benefit from loop diuretics 
since they retain their utility at a creatinine clearance (CrCl) < 5 
mL/min while distal tubule diuretics lose their efficacy at a CrCl 
< 40 mL/min. However, thiazides and thiazide-like diuretics 
(e.g. metolazone), provide synergistic effects when administered 
thirty min prior to a loop diuretic to inhibit compensatory distal 
tubular reabsorption, which avoids having to increase loop 
dosages and limits long-term exposure to high-dose diuretics.9, 10
Higher doses of diuretics are required with a fall in the glomerular 
filtration rate, whether in chronic kidney disease (CKD), acute 
kidney injury, or hypoperfusion states. Drug secretion into the 
lumen of the nephron is diminished with retention of competing 
anions in renal failure and fewer functioning nephrons limit the 
maximal response of the drug. Moderate CKD can require 80 mg 
of intravenous furosemide (or bumetanide 2-3 mg, or torsemide 
20-50 mg) while 200 mg may be required with severe CKD (or 
bumetanide 8-10 mg, or torsemide 50-100 mg).11
Renal tubular secretion of furosemide is typically normal in 
nephrotic syndrome but since the diuretic is bound to urinary 
albumin, the lack of active drug blunts the diuretic response. If 
urinary albumin exceeds 4 g/L, 50-66% of the drug is bound to 
albumin and inactive.12 Appropriate measures include increasing 
doses, frequency, and using thiazides in conjunction with 
loop-diuretics. Avoidance of renal vasoconstriction mediated by 
non-steroidal anti-inflammatory drugs (NSAIDs) also improves 
diuretic responsiveness.
Portal Hypertension
Limited cardiac output in heart failure decreases loop diuretic 
secretion into the tubular lumen from decreased renal perfusion, 
while cirrhosis through renal vasoconstriction. The mainstay 
diuretic in managing moderate-volume ascites in cirrhosis is 
either spironolactone (50-200 mg/day) or amiloride (5-10 mg/
day) with low doses of furosemide (20-40 mg day) to supplement 
natriuresis if peripheral edema is present. The recommended 
daily weight loss in these patients without and with peripheral 
edema is up to 1 lb and 2 lbs respectively to prevent pre-renal 
failure.13 Patients with large-volume ascites and marked 
abdominal discomfort impairing activities of daily living can 
ideally undergo therapeutic paracentesis or attempt maximum 
doses of spironolactone (400 mg/day) and furosemide (160 
mg/day). These patients typically present with urinary sodium 
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< 10 mM and normal free-water excretion and serum sodium. 
When free-water excretion is impaired, dilutional hyponatremia 
develops spontaneously or with increased fluid intake.
Patients with anasarca can have 2-3 L of fluid removed daily 
without reduction in plasma volume whereas patients with 
isolated ascites (no peripheral edema), can only have 300-500 
mL/day of ascitic fluid mobilized daily without risking 
azotemia.14 The azotemia will improve after ceasing diuresis and 
fluid repletion whereas hepatorenal syndrome, often mistakenly 
linked to diuretic use, will continue to worsen. Similar to patients 
in acute or chronic heart failure, rapid diuresis in cirrhotic 
patients leads to decreased cardiac output. Diuretic-resistant 
ascites is defined by either inability to mobilize ascites despite 
sodium restriction (24-hour urine with < 78 mEq sodium or a 
random urine sodium < urine potassium) and maximum oral 
diuretics (spironolactone 400 mg/day and furosemide 160 mg/
day) or prohibitive diuretic-related complications (progressive 
azotemia, hepatic encephalopathy, or progressive electrolyte 
imbalance) in the absence of NSAIDs.15 Ceasing beta-blockers, 
angiotensin receptor blockers, or angiotensin converting enzyme 
inhibitors, can improve blood pressure, tissue perfusion, renal 
function, and diuretic responsiveness. 
Discussion
Compounding renal insufficiency with reduced intestinal 
motility, perfusion, mucosal edema and tolerance to oral 
diuretics may also project a need for intravenous therapy; 
however, awareness of the pharmacokinetics and dynamics of 
diuretics will often provide solutions.16 All diuretics need to 
attain a minimal rate of tubular excretion before a response is 
attained. Minimal response at a given dose indicates the dose 
was effective in achieving the minimal rate but the effect was 
short-lived; a twice daily regimen can achieve the desired urine 
output. However, no response following a diuretic suggests 
doubling the dose (maximum furosemide dose 320-400 mg PO 
or 160-320 mg IV) for diuresis.11 Between the minimum drug 
excretion rate required for initiating diuresis and a plateau where 
further drug excretion does not produce additional output, lies 
the critical curve where drug excretion correlates to the extent 
of naturesis. 
Tolerance exists even with consecutive multiple intravenous doses 
of furosemide in healthy individuals where naturesis/diuresis 
decreases with compensatory increased renin and decreased 
atrial natriuretic peptide.17 Outpatient diuretic tolerance can 
be compounded by renal compensatory mechanisms or an 
impaired natriuretic response to furosemide if on a low sodium 
diet.18 A few weeks of a diuretic dose will activate sodium 
retaining forces (e.g. renin-angiotensin II-aldosterone, norepi-
nephrine, or reduction in system blood pressure) to achieve 
steady-state in sodium intake and excretion.19 However, poor 
adherence to sodium restriction on the other hand will prevent 
net fluid loss despite adequate diuresis; greater than 100 mEq 
sodium (2 g sodium = 88 mEq) in a 24-hour urine collection 
suggests non-compliance.20 
Approaches that use higher doses of the drug, increased 
frequency, or synergy with other diuretics are required to 
overcome sodium retention. Substantial responses in diuretic 
naïve patients are likely due to a lack of these adaptations. Acute 
decompensated patients on outpatient doses of furosemide doses 
≥ 120 mg/day benefit from initial bolus doses inpatient while 
outpatient regimens with lower doses responded better to initial 
continuous dosing.21 Other loop diuretics such as bumetanide 
and toresemide boast of superior bioavailability (Table 1) and 
can be considered first-line agents over furosemide in certain 
cases. In heart failure patients, toresemide has been shown to 
decrease left-ventricular remodeling, rates of hospitalization, 
Table 1. Pharmacodynamics and kinetics of common diuretics
Onset (min) Peak (hours) Duration (hours) τ½ (hours) Bioavailability (%)
Furosemide (PO) 30 – 60 1 – 2 6 – 8 0.5 – 2* 47 – 64
Furosemide (IV) 5 2
Bumetanide (PO) 10 1 4 – 6 1 – 1.5 59 – 89
Torsemide (PO) 60 1 – 2 6 – 8 3.5† 80
Ethacrynic acid (PO) 30 2 12 2 – 4
Metolazone (PO) 60 ≥ 24 20
Spironolactone (PO) 3 – 4 48-72 1.3‡
* End-stage renal disease: half-life (τ½) increases to 9 hours 
† Cirrhosis: half-life (τ½) increases to 7-8 hours 
‡ Active metabolites have the following half-lives (τ½): canrenone: 10-23 hours; 7-alpha-spirolactone: 7-20 hours 
Loop diuretic equivalency: furosemide 40 mg PO = furosemide 20 mg IV = bumetanide 1 mg PO/IV = torsemide 20 mg PO/IV = ethacrynic acid 50 mg PO 
(sulfonamide alternative)
(Adapted from Lexi-Comp)
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and mortality over furosemide.6 When compared to furosemide, 
bumetanide was more effective in reducing edema in patients 
with nephrotic syndrome and dyspnea in heart failure.6 Certain 
localized edematous states secondary to venous insufficiency, 
moderate-severe lymphedema, or malignant ascites require 
caution against depleting plasma volume when using diuretics.14
Given the multifactorial causes of diuresis failure, exploring the 
nature of the edema state, utilizing a different diuretic agent or 
considering an additional agent, changing the route, frequency 
(Table 1), or the dose, can be attempted. The bioavailability of 
a diuretic will influence the dose required for a response while 
the plasma half-life will determine frequency of administration. 
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